Two Drugs Stir Hope for Treatment of Deadly Pancreatic Cancer
The New York Times • • business
Key Points:
- Two experimental treatments for pancreatic cancer are showing promising results in early clinical trials, raising hope for a disease with historically poor outcomes.
- The data, presented at a cancer conference in San Diego, comes from a small patient group and has not yet undergone peer review or regulatory approval.
- Pancreatic cancer causes over 50,000 deaths annually in the U.S., with a five-year survival rate of only 13 percent, highlighting the urgent need for more effective therapies.
- One drug, daraxonrasib, reportedly doubled patients' life expectancy to over 13 months compared to under seven months with chemotherapy in a late-stage trial.
- Experts describe these findings as unprecedented, though the treatments remain experimental and are not yet approved for general use.
